Summary
Abbott Laboratories (ABT) filed an 8-K on July 20, 2017, to report its second-quarter 2017 financial results. The filing primarily announces the results of operations for the quarter, which are detailed in a press release furnished as Exhibit 99.1. Investors should note that Abbott uses non-GAAP financial measures, which exclude items such as acquisition and restructuring expenses, cost reduction initiatives, gains from business sales, currency devaluation, and tax resolutions, to provide a clearer view of ongoing operational performance. While these non-GAAP measures are used by management for internal assessment and offer investors a way to evaluate underlying business performance, they should be considered alongside GAAP measures. The primary purpose of this 8-K is to make these second-quarter results publicly available, with the detailed financial figures and management's discussion contained within the referenced press release.
Key Highlights
- 1Abbott Laboratories announced its second-quarter 2017 financial results via an 8-K filing on July 20, 2017.
- 2The report includes a press release (Exhibit 99.1) detailing the Q2 2017 financial performance.
- 3Abbott utilizes non-GAAP financial measures to present earnings, excluding specified items to highlight ongoing operational performance.
- 4Excluded items include acquisition/restructuring costs, cost reduction charges, gains on business sales, Venezuela devaluation expenses, and tax resolutions.
- 5Intangible amortization expense is also excluded in non-GAAP reporting for enhanced visibility.
- 6Management believes these non-GAAP measures offer valuable insights into the company's underlying business performance.
- 7Investors are advised to consider these non-GAAP measures in conjunction with, not as a substitute for, GAAP financial measures.